For as long as I have been in practice in the East Bay (almost forty years), the Bay Area Tumor Institute (BATI) has been the most responsive, important, and successful contributor to the never-ending efforts of East Bay physicians, oncology nurses, and hospitals to cope with the ever-changing challenges of providing the best possible care to our patients. I cannot imagine how different this community would be without BATI.

The Bay Area Tumor Institute first brought clinical trials research in cancer to our community in 1979, enabling East Bay patients and their physicians to participate in the development of every new treatment for pediatric cancer, breast cancer, and many other malignant diseases of children and adults. Our participation in this complex and difficult research has significantly improved treatments nationwide, extended the lives of many, and cured others who would have been lost.

Especially noteworthy are the Institute’s achievements as a national leader in the recruitment of minority and underserved populations to landmark cancer therapy and prevention studies. Remarkably, more than 50 percent of our research patients are members of historically underserved minority groups.

The Bay Area Tumor Institute has brought university and comprehensive cancer center level clinical research opportunities to patients in the East Bay community. For many, there is no longer a need to cross bridges and struggle through endless traffic to obtain these most advanced forms of investigational cancer therapy.

The Bay Area Tumor Institute has created extraordinary opportunities for community-based cancer patients. We will continue to offer the most advanced therapeutic options to our patients while always seeking to find more effective, more durable, and less toxic treatments.

Kind regards,

Lisa Bailey, M.D., F.A.C.S.

Principal Investigator, Bay Area Tumor Institute
NCI-Community Oncology Research Program (NCORP)
The Mission

Since its founding in 1972, the mission of the Bay Area Tumor Institute (BATI) has been to improve the rates of cure or disease-free survival for cancer patients, via the scientific discovery of more effective and humane ways to deliver cancer care through participation in the nation’s most advanced, community-based, NCI-approved research efforts to cure and control cancer.

BATI has been a member of the clinical research program of the National Cancer Institute for the past 42 consecutive years. Beginning in 1979 and continuing through 2026, BATI has been awarded long-term research grants to participate in the “NCI-Community Oncology Research Program” (NCORP). Via the NCORP designation, BATI has the rare opportunity to provide pediatric and adult cancer patients in the East Bay with access to the most advanced forms of genetic and immunotherapy currently being tested in the United States.

With the award of the NCORP grants, the Bay Area Tumor Institute has reached a watershed moment, providing an opportunity to work as a full partner with the top cancer researchers, universities, and comprehensive cancer centers across the nation. With NCORP, we are making the dream of receiving optimal care while remaining in the East Bay for treatment a life-giving reality for those cancer patients who need access to the most advanced forms of investigational cancer treatment.
Since 2009, the BATI-NCORP has received fifteen awards from the National Cancer Institute. Each award acknowledged superior levels of patient participation in our nation’s most advanced community-based clinical oncology research program. Of very special note, in the years between 2013 and 2017, BATI pediatric oncologists were annually recognized for achieving the Highest Nationwide Enrollment of Treatment Clinical Trials.

**2009**

**SILVER CERTIFICATE OF EXCELLENCE**

in Patient Enrollments to
Treatment and Cancer Control Trials

**2010**

**SILVER CERTIFICATE OF EXCELLENCE**

in Patient Enrollments to
Treatment and Cancer Control Trials

**2011**

**GOLD CERTIFICATE OF EXCELLENCE**

in Patient Enrollments to
Treatment and Cancer Control Trials

**2012**

**GOLD CERTIFICATE OF EXCELLENCE**

in Patient Enrollments to
Treatment and Cancer Control Trials

Recognizing Dr. James Feusner

**GOLD CERTIFICATE OF EXCELLENCE**

in Patient Enrollments to
Treatment and Cancer Control Trials

Recognizing Dr. Lili Wang
2012 (CONTINUED)
SILVER CERTIFICATE OF EXCELLENCE
in Patient Enrollments to
Treatment and Cancer Control Trials
Recognizing Dr. Jon Greif

2013
HIGHEST NATIONWIDE ENROLLMENT
OF TREATMENT CLINICAL TRIALS
Recognizing Bay Area Tumor Institute
and Dr. James Feusner

PLATINUM CERTIFICATE OF EXCELLENCE
Recognizing Bay Area Tumor Institute

SILVER CERTIFICATE OF EXCELLENCE
in Patient Enrollments to
Treatment and Cancer Control Trials
Recognizing Dr. Jon Greif

2014–2017
HIGHEST ACCRUING TREATMENT NCORP
INVESTIGATOR FOR THE PERIOD 2014–2017
Recognizing Dr. Carla Golden

2018
A HIGHEST COG NCORP
ENROLLING INSTITUTION
Recognizing Dr. Carla Golden and
Children’s Hospital Medical Center, Oakland

2019
SILVER CERTIFICATE OF EXCELLENCE
Recognizing BATI-NCORP Network

2021
CERTIFICATE OF EXCELLENCE
in Pediatric Cancer Care Delivery
Recognizing Dr. Carla Golden
UCSF Benihoff Children’s Hospital, Oakland
The goal of the Bay Area Tumor Institute’s clinical trials research is to provide cancer patients and high-risk populations in the East Bay with the most advanced and promising forms of cancer therapy and cancer prevention being offered in the United States and abroad.

Genetic Mutation Targeted Immunotherapy Treatment Trials” are at the forefront of the most advanced forms of cancer treatment and continuing research efforts. Recent advances in deciphering the cancer genome have enabled the development of personalized targeted therapies that have fundamentally changed our approach to cancer treatment. Drugs such as Pembrolizumab, Atezolizumab, Abemaciclib, GDC-0084, Entrectinib, Pertuzumab, Nivolumab, Ipilimumab, Tucatinib, Sacituzumab Govitecan, Olaparib, Avelumab, Cabozantinib, Crizotinib, Binimetinib, Encorafenib, and seven others inhibit molecular pathways that are critical to tumor growth and survival. The discovery of “genetic drivers” has led to a new molecular classification of tumors, distinct from the traditional histologic classification. This capability potentially allows the selection of patients who are most susceptible to a specific therapy, also known as “targeted therapy.”

Examples of the types of cancers that BATI physicians can now treat utilizing NCI-approved “Genetic Mutation Targeted Immunotherapy Treatment Trials” include:

- Triple-Negative Breast Cancer
- HER2+ Breast Cancer
- Stage III Colon-Rectal Cancer
- Non-Small Cell Lung Cancer
- Molecular Analysis for Therapy Choice (MATCH)
- Check Point Blockage for Specific Rare Tumors
- Brain Metastasis
- Melanoma
- Skin Cancer
The BATI-NCORP also offers patients the opportunity to participate in major nationwide NCI-approved clinical trials of new ways to prevent, diagnose, and treat cancer utilizing surgery, radiation, gene therapy, and chemotherapy. Equally important are efforts to discover methods to improve quality of life, reduce recurrence, optimize symptom reduction, eliminate over- and under-diagnosis, and manage precancerous lesions by utilizing advanced imaging and genetic tools.

Examples of a few of the multi-disciplinary cancer treatment, prevention, and symptom management research trials offered by BATI include:

- Brain Protocols
- Breast Protocols: Neoadjuvant
- Breast Protocols: Stages I–IIIA
- Breast Protocols: Locally Advanced / Recurrent / Metastatic
- Breast Protocols: Other Types / Stages
- Cancer Care Delivery Research
- Cancer Control / Symptom Management
- Cutaneous Protocols
- Germ Cell Protocols
- GI Protocols: Colon-Rectal
- GU Protocols: Bladder
- GU Protocols: Renal
- GU Protocols: Multiple Sites
- GYN Protocols: Ovary
- Head and Neck Protocols
- Lung Protocols: Non–Small Cell
- Melanoma
- Advanced Neuroendocrine Tumors

For the most up-to-date list and detailed description of NCI-approved clinical trials for use by BATI investigators, please visit www.bati.org and click on “clinical research.”
Each of the more than 6,000 people who have taken part in NCI clinical trials research conducted by the Bay Area Tumor Institute since 1979 has a personal reason for joining. The quotations that appear here exemplify responses from participants in screening, prevention, and therapeutic clinical trials.

“Knowing that these trials are approved by the National Cancer Institute and are being conducted at the nation’s leading cancer centers gives me a great sense of confidence that my treatment will be best for me and will contribute to improved care for future patients.” —B.S.

“I joined a cancer screening trial to help future generations of women learn about their cancers at the earliest possible moment.” —A.L.

“I participated to help future patients and, hopefully, to prolong my life.” —J.J.
“I wanted my encounter with cancer to generate the scientific knowledge so vital to the improvement of future patient care and improved rates of survival.” —R.E.

“My participation in this trial because, as a science educator, I understand that clinical trials are vital to advance our knowledge and medical treatments.” —S.K.

“When I was first diagnosed with breast cancer in 2005, I was focused on my own recovery. When I heard that I could participate in a trial for targeted radiation therapy, I jumped at the chance to help other women, and myself, benefit from the latest technology (but the additional layers of surveillance were also a comfort!).” —B.J.

“There are many ways we can create a legacy for our family. There are fewer opportunities to create a legacy for humanity. Participating in clinical trials gave me a chance to do both.” —A.W.
Cancer affects all population groups in the United States. Certain groups, however, may bear a disproportionate burden of cancer compared with other groups. Since its Oakland-based founding in 1972, the Bay Area Tumor Institute has engaged and served all members of our diverse East Bay community, including those who have been historically “medically underserved.” Today, more than half of all participants in our research program are classified by the NCI as low-income, non-English-speaking at home, medically underserved, or children. These patients and “populations at high risk” are a substantial focus of our research that seeks to identify and address health disparities in patient cure, long-term survival, recurrence of disease, cancer prevention, and after-treatment quality of life measurements. The BATI-NCORP accelerates the adoption of new knowledge by oncology specialists and health care systems as a way to expand participation in lifesaving research, irrespective of barriers related to economics, race, education, or ethnicity.

The following graph describes the patients (as they have described themselves) served during the past five years. Simply stated, providing equal access to cancer prevention research opportunities and advanced clinical research treatments, at no financial cost to the participant or patient in the community setting, is at the core of our mission.
THE IMPORTANCE OF YOUR FINANCIAL SUPPORT

To fulfill its obligation to offer cancer patients every possible opportunity for long-term survival or cure, the Bay Area Tumor Institute depends upon the support of its many long-term and highly generous donors. No patient has ever received a bill from the Bay Area Tumor Institute. All services are provided to cancer patients, hospitals, and physicians without charge. Money is simply not part of the equation when cancer patients need our help.

Whether a patient participates in clinical research and receives the most expensive investigational medications; requests detailed information regarding their diagnosis or treatment; seeks help in decision-making; or asks for highly specific direction in navigating the complex cancer care system, BATI does not send a bill or ask for a donation. Our services are provided to anyone who needs and asks for our help to understand and find the best solution to their experience with cancer.

Although our services are free of charge, the work is not free of cost. Major expenses are incurred in operating a community-based clinical research program. Our out-of-pocket costs per patient can easily exceed $15,000, in arranging for optimal cancer treatments, obtaining extraordinarily expensive investigational drugs, protecting patients from potential medical and financial harm, and ensuring lifetime follow-up.

Many newly diagnosed or recurrent cancer patients depend on our website as well as the personalized informational and navigational services that are provided without cost.

For a deeper insight into the value and services of the Institute, we invite you to meet with Barry Siegel, President of the Institute.

Please call [510] 465-8571 for further information or to schedule an appointment.
DONORS

Loyal and generous friends make it possible to offer cancer patients access to the most advanced forms of investigational treatment. Deepest appreciation is offered to the following donors for extraordinary generosity.

SEPTEMBER 1, 2020–AUGUST 31, 2021

VISIONARY DONORS

Anonymous in honor of
Ms. Kellie Johnson Abreu
Mr. and Mrs. Steven Abreu
Anderson Family Fund
(in memory of Theodore R. Purcell, M.D.)
Lisa Bailey, M.D., F.A.C.S.
Mrs. Virginia Furth
Mr. and Mrs. Umberto Gibin
Mr. and Mrs. Max Gray
Nancee Hirano, R.N., M.S., A.N.P., A.O.C.N.,
and Mr. Terence Shinsato
Ms. Arlene Inch
Mr. and Mrs. Robert M. Jasper
T. Lloyd Kelly Foundation
Mr. and Mrs. Bruce Lymburn
Mr. and Mrs. William Quinby
Mr. Peter Read
Mr. and Mrs. Barry Siegel

MAJOR DONORS

Emily Abe, M.D., F.A.C.S.
Mrs. Dale Block
Mr. L. Dale Crandall
Mr. C. R. “Buzz” Gibb
Mr. and Mrs. Thomas Johnson
Tom Lee, M.D.
McCorduck Properties, LLC
Mrs. Ruthie McLeod
Mr. and Mrs. Alan Price
Mr. and Mrs. Jon Reynolds
Ms. Joanne Rose
Mr. and Mrs. David Ruegg
Brenda Shank, M.D., Ph.D.
Mr. and Mrs. Glenn Shannon
Mr. Matt Sitzmann
Ms. Sally Tomlinson
Ligaya Yadao, R.N., M.S.

SUPPORTING DONORS

Dr. and Mrs. Wise Allen
Audrey Berman, Ph.D., R.N.
Dr. and Mrs. Norman Cohen
Mr. and Mrs. Sheldon Crandall
Mrs. Beth Deatley
Mrs. Joyce Dobbel
Ms. Maureen Dunn
Mr. and Mrs. Gary Egkan
Dr. and Mrs. Donald Godbold and family
Mr. and Mrs. Christian Green
Jon Greif, D.O., F.A.C.S.
Mr. and Mrs. Gordon Haberfelde
Head-Royce School
Mr. and Mrs. Vic Hebert
Mr. and Mrs. Eugene Hill
Ms. Cici Hoover
Mr. and Mrs. Grant Inman
Ms. Nancy Jacobs
KaiserAir, Inc.
Mr. Fred Karren
Mr. and Mrs. Mark Lachtman
Ms. Kathryn Lawrence
Mr. and Mrs. C. K. Lee, M.D.
Mr. and Mrs. Greil Marcus
Mr. and Mrs. Ed Means
Mr. Ivan Meyerson
Overaa Family Trust
Mr. George Peyton
Mr. and Mrs. Parker Phillips
Mrs. Maggie Plageman
Mr. and Mrs. Drew Robarts
Lionel Schour, M.D.
Ms. Cassandra Warren
Ms. Sunnee Weinburg
Mrs. Betsy Willcuts
Ms. Gayle Young
Mr. and Mrs. Phil Zimmerman
Through the remarkable generosity and dedication of physicians, nurses, dentists, and social workers, cancer patients are never asked to pay for services provided by the Institute. Due to limitations of space, only a partial list of volunteers follows, although many others deserve our gratitude as well.

Lisa Bailey, M.D., F.A.C.S.
Barbara Beach, M.D.
Audrey Berman, Ph.D., R.N.
Patricia Calloway, B.S.N.
Michael Cassidy, M.D.
Maria Cho, R.N., Ph.D.
Norman R. Cohen, M.D.
Bo Dahlstrom, M.S.
Bao Dao, M.D.
James Feusner, M.D.
John Ganey, M.D.
Lisa Garcia, R.N.
Carla Golden, M.D.
Debra Gologorsky, M.D.
Jon Greif, D.O., F.A.C.S.
Teri Gwin, Ed.D., M.S.N., F.N.P.
Michael Gynn, M.D.
Beverly Hart-Inkster, R.N., O.C.N.
Cindy Hellman-Wylie, R.N., N.P.
Shoba Kankipati, M.D.
Linda Kelly, L.C.S.W.
Tashmin Khan, R.N.
Miriam Korah, M.D.
Tom K. Lee, M.D.
Vivian LeTran, D.O.
Michael Mannion, R.T.T., C.M.D.
Natalie Marshall, M.D.
Jane McCormick, M.D.
Ostap Melnyk, M.D.
Miroslav Nikolic, Ph.D.
Carolyln Parma, M.D.
Bimal Patel, M.D.
Gautam Prasad, M.D.
Angeles Price, R.N., M.S.
Ms. Martha Rodriguez
Gopal Sachdeva, M.D.
Brenda Shank, M.D., Ph.D.
Elaine Shingleton, R.N., M.S.
Nikki Singh, M.D.
Martha Tracy, M.D.
Valery Uhl, M.D.
Lili Wang, M.D.
Ligaya Yadao, R.N., M.S.

The Bay Area Tumor Institute is tax exempt under Section 501(c)(3) of the Internal Revenue Service Code. Contributions are tax deductible. The Institute’s taxpayer ID number is 94-2176753.
BOARD OF DIRECTORS
AND PROFESSIONAL STAFF

OFFICERS
Ms. Kellie Johnson Abreu
Chair
Mrs. Dale Forrest Block
Co-Chair
Mr. Barry B. Siegel
President
Ms. Sharon Omega
Corporate Secretary

DIRECTORS
Lisa Bailey, M.D., F.A.C.S.
Jon Greif, D.O., F.A.C.S.
Nancee M. Hirano, R.N., M.S., A.N.P., A.O.C.N.
Mrs. Cici Hoover
Ms. Arlene G. Inch

Linda Kelly, L.C.S.W.
Tom K. Lee, M.D.
Angeles Price, R.N., M.S.
Brenda Shank, M.D., Ph.D.
Ligaya Yadao, R.N., M.S.

SENIOR DIRECTORS
Audrey Berman, Ph.D., R.N.
W.A. “Chip” Brown
Mrs. Alan C. Furth
Max D. Gray
Robert and Ellen Jasper
William A. Quinby, Esq.

LEGAL COUNSEL
Elizabeth Cannon and Richard Lund
Plageman, Lund & Cannon, L.L.P.

PROFESSIONAL STAFF
Ms. Sharon Omega
Clinical Research Director
Ms. Melody Chin
Clinical Research Associate
Ms. Joanne V. Heath, C.C.R.A.
Clinical Research Associate
Ms. Leah Radke
Executive Assistant

AUDITORS
Jones, Henle & Schunck

DESIGN AND COMPOSITION BY WILSTED & TAYLOR